1. Home
  2. HBAN vs UTHR Comparison

HBAN vs UTHR Comparison

Compare HBAN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huntington Bancshares Incorporated

HBAN

Huntington Bancshares Incorporated

HOLD

Current Price

$15.00

Market Cap

28.4B

Sector

Finance

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$523.84

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBAN
UTHR
Founded
1866
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.4B
23.9B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
HBAN
UTHR
Price
$15.00
$523.84
Analyst Decision
Buy
Buy
Analyst Count
17
14
Target Price
$19.38
$531.79
AVG Volume (30 Days)
25.2M
497.9K
Earning Date
04-16-2026
04-29-2026
Dividend Yield
4.09%
N/A
EPS Growth
N/A
13.07
EPS
N/A
27.86
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$50.66
$7.05
Revenue Next Year
$9.04
$13.30
P/E Ratio
$12.87
$18.93
Revenue Growth
N/A
2.38
52 Week Low
$11.92
$266.98
52 Week High
$19.44
$548.12

Technical Indicators

Market Signals
Indicator
HBAN
UTHR
Relative Strength Index (RSI) 28.84 56.10
Support Level N/A $464.92
Resistance Level $16.28 $542.66
Average True Range (ATR) 0.39 13.44
MACD -0.09 0.51
Stochastic Oscillator 9.81 70.23

Price Performance

Historical Comparison
HBAN
UTHR

About HBAN Huntington Bancshares Incorporated

Huntington is a regional US bank with over $200 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: